Future agents and navigating personalised treatment in IBD
The numerous sessions discussing novel treatments at ECCO 2019 made it clear that IBD is an exciting therapy area with many new treatments on the horizon. Novel IBD treatments include anti-integrin therapies, anti-IL-12/23 and anti-IL-22 monoclonal antibodies, JAK inhibitors, anti-adhesion molecules and S1P receptor modulators. While new treatments will offer more choice for patients and the potential for more personalised treatment in IBD, studies testing the efficacy and safety of novel combinations will be required. In addition, presenters highlighted the need for head-to-head comparative trials to help guide treatment decisions.
IBD is a chronic and debilitating disease that has a profound effect on a patient’s life. Currently, there is no cure for IBD; however, seeing the broad range of developments in basic science, translational medicine and clinical management from some of the world’s top scientists at the ECCO Congress, the future management of this condition is certainly looking positive.